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(57) ABSTRACT 
It is the object of the current invention to provide methods and 
compositions relating to the expression ofvankyrin proteins 
in cell lines to increase their viability, longevity and capacity 
for protein production. The inventors have discovered that the 
expressionofP-ank:-1 and f -ank:-3 proteins in cell culture has 
increased the cells' longevity and capacity for endogenous 
and/or heterologous target protein production. Specifically, 
the present invention relates to the enhanced expression of 
endogenous and/or heterologous target proteins/polypeptides 
in recombinant cells that are also expressing P-ank:-1 and/or 
I2 -ank-3 protein compared to expression host cells that are not 
expressing P-ank:-1 and/or f-ank:-3 protein. 
24 Claims, 6 Drawing Sheets 
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P-ankyrin-1: eDNA (SEQ ID NO: 1) 
ATGGAGATTTCTCAAATTCGAAAGCTATTCGGTAAAAACCGCGTCACGAAAAATACCATATTTC 
ACGAGCTTGCCCACGCTGGATCATTGACACTACTGTACCGGGTTCGAGACAACATTGACGAGCC 
ATGCAGCTCTATCCTGCAAGAGGTTAATGCTGATGGAGACTATAGTATCCATGTG~CGGCAAAG 
ACGCACCGAGGACAGCTTGCAGTGAGGATCATACAGGTGCTACTAGAGTTAGGGGCAAACCTGA 
ATGCGAAAGATCGTGTCTGGAACTTTACTGTACTGCATGTCGCAGTTGAGCGAGACGATTACGT 
CCTCGCAAAGTGGCTGCGCCATCACCCACAAATTGATTTGGATGCAAGAGGTTGGGATGGACTT 
ACGGCACATGAAACGTCGTTGATAACGTGCAACAAAGAGATGATGGATATTTTCCGAACCGACG 
GTGTTAACAGAGCCGGTGGTACAGAGCCGAAAGTGAATGAAAGTACATCGAATGACAATCAGCA 
T 
P-ankyrin-1: Protein (SEQ ID NO: 2) 
MEISQIRKLFGKNRVTKNTIFHELAHAGSLTLLYRVRDNIDEPCSSILQEVNADGDYSIHVAAK 
THRGQLAVRIIQVLLELGANLNAKDRVWNFTVLHVAVERDDYVLAKWLRHHPQIDLDARGWDGL. 
TAHETSLITCNKEMMDIFRTDGVNRAGGTEPKVNESTSNDNQH 
12-ankyrin-3: eDNA (SEQ ID NO: 3) 
ATGGAAAATTCTCAAATTGCAAAGCTGTTCGGTACAAACTGGGTCACGAAAAATACCATATTTC 
ACGAGCTTGCCCACGCTGGATCGTTGACACTTCTTCACCGGGTTCGACACAACATTCAAGAGCC 
ATGCAGCTCTATCCTGCAAGAGGTTAATGCTAATGGAGACTATAGTATTCATGTGGCGGCAAAA 
ACGCACCGAGGACAGCTCGCAGTGAGGATCATTCAGATACTACTGGAATTGGGGGCTAATCTGA 
ATGCAAGAGATCGTGTCTGGAACTTTACTGTACTGCATGTCGCAGTTGAGCGGGAGGATTACGT 
CCTCACAATGTGGCTGCGCCATCACCCACAAATGGATTTGAATGCGAGAGGTTTCGCTGGACTT 
ACGGCACATCAAATGGCGTTGATGTCGTGCGACAGAAAGATGATGGATATTTTCCGAACCGACG 
CTGTATACGGAGCCGGTGGTTCAGAGCCGAAAGTGAATGAAAGTACATCGAATGACAATCAGCA 
T 
12-ankyrin-3: Protein (SEQ ID NO: 4) 
MENSQIAKLFGTNWVTKNTIFHELAHAGSLTLLHRVRHNIQEPCSSILQEVNANGDYSIHVAAK 
THRGQLAVRIIQILLELGANLNARDRVWNFTVLHVAVEREDYVLTMWLRHHPQMDLNARGFAGL 
TAHQMALMSCDRKMMDIFRTDAVYGAGGSEPKVNESTSNDNQH 
Figure 3 
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Approximate Yields of Vankyrin Proteins off of Nickei-NTA Columns 
(QIAGEN) 
Average Concentration of Eluted Proteins {from 25ml Aggroximate Yield 
Culture) {1 L Culture) 
P-ank-1 1.22 mg/ml (In 2.05mL) 100.04 mg/L 
P-ank-2 0.9035 mg/mL (in 1.50ml) 54.21 mg/L 
P-ank~3 1.009 mg/ml (in 1.360ml) 54.89 mg/L 
P-ank-4 0.9904 mg/ml (in 1.500ml) 59.42 mg/L 
12-ank-1 0.9382 mg/mL (in 1.500ml) 56.29 mg/L 
12-ank-2 1.002 mg/ml (in 1.500ml) 60.12 mg/l 
12-ank-3 1.18 mg/mL (in 2.050ml) 96.76 mg/L 
I I 
Approximate purity of eluted proteins: 60-75% 
Proteins were collected 1 day prior to apparent cell lysis in infected Sf9 Cells 
I I 
Yield Calculation: 1.22mg/ml X 2.05 mL = 2.501 mg 
2.501 mg/ .025L Culture = 100.04 mg/L 
---
Figure 6 
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VECTORS AND METHODS FOR ENHANCED 
CELL LONGEVITY AND PROTEIN 
EXPRESSION 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to the fields of nucleic acid con-
structs and cell lines that allow for the increased expression of 
endogenous or heterologous target protein. 
2. Background 
10 
The immediate challenge created by the genomics era is 
the production of the novel proteins to understand their func-
tion. Current methods of expressing genes in a marmnalian 
cell include the use of viral vectors, such as those which are 15 
derived from retroviruses, adenoviruses, herpes viruses, vac-
cinia viruses, polio viruses, sindbis viruses, or adena-associ-
ated viruses. Other methods of expressing an exogenous gene 
in a mammalian cell include direct injection of DNA, the use 
of ligand-DNA conjugates, the use of adenovirus-ligand- 20 
DNA conjugates, calcium phosphate precipitation, and meth-
ods which utilize a liposome- or polycation-DNA complex. 
Due to its advantages in versatility and speed, the Bacu-
lovirus Expression Vector System (BEYS) used in conjunc-
tion with insect cells has become well-established for the 25 
production of proteins, particularly recombinant glycopro-
teins. Baculovirus mediated protein expression provides cor-
rect folding of recombinant protein as well as disulfide bond 
formation, oligomerization and other important post-transla-
tional modifications that impart proper biological activity and 30 
function. With regard to protein folding and post-translational 
processing, insect cells are second only to marmnalian cell 
lines when expressing a eukaryotic protein, for example. The 
frequent use of baculovirus arises from the relative ease and 
speed with which a heterologous protein can be expressed on 35 
the laboratory scale and the high chance of obtaining a bio-
logically active protein. Insect cells can be grown on serum 
free media which is an advantage in terms of costs as well as 
of biosafety. For large scale culture, conditions have been 
developed which meet the special requirements of insect 40 
cells. 
2 
(1983). Several advantages may exist when employing the 
BEY system. One of these advantages is the strong polyhe-
drin promoter which directs a high level of expression of the 
inserted heterologous nucleic acid encoding the target 
polypeptide. The newly expressed heterologous target pro-
tein accumulates in large amounts within these infected insect 
cells. Thus, as a result of the relative strength of the polyhe-
drin promoter, many different gene inserts can be expressed at 
very high levels. 
In addition to providing a high expression level, another 
advantage of the BEY system is the ease with which these 
baculoviruses are produced and identified. This process 
begins by co-transfecting wild -type viral DNA and a "transfer 
vector" into susceptible host cells. A transfer vector is defined 
as a bacterial plasmid which contains a desired gene directly 
3' to the polyhedrin promoter, as well as long viral sequences 
flanking the promoter on the 5' side. During cotransfection, 
homologous recombination occuring between viral and 
transfer vector DNA will produce a small percentage of viral 
genomes in which the polyhedrin gene has been replaced by 
the desired heterologous nucleic acid encoding the target 
polypeptide (0.1-5.0% ). The wild-type progeny can be differ-
entiated from the recombinant progeny by a conventional 
viral plaque assay. Recombinants in which the polyhedrin 
gene has been replaced, can be identified by their occlusion-
negative plaque phenotype observed in a background of 
occlusion-positive wild-type plaques. 
Because the polyhedrin gene is a non-essential gene for 
productive viral infection, another advantage ofbaculovirus 
expression vectors is that the recombinants are viable, helper-
independent viruses. Also, baculoviruses only infect Lepi-
dopteran insects; thus, they are noninfectious for vertebrates, 
and are, therefore, relatively safe genetic manipulation 
agents. 
Notwithstanding the successes of BEYS and other systems 
for expression of heterologous proteins in insect and mam-
malian cell culture, maintenance of the viability of trans-
formed or transfected cell cultures remains a capricious 
undertaking. Many laboratories refer to tissue culture as a 
"black art," due to the numerous variables that make it diffi-
cult to determine solutions when problems arise. An intensive 
and time-consuming systematic approach that examines the 
symptoms and meticulously retraces each step in the culture 
In nature, baculoviruses are double-stranded DNA-con-
taining viruses that infect a variety of different insect species. 
The nuclear polyhedra sis viruses, which comprise subgroup 
A of the Family Baculoviridae, induce the formation of 
paracrystalline occlusion bodies in the nuclei of infected host 
cells. These occlusion bodies are composed primarily of a 
single viral protein which is expressed at very high levels 
(polyhedrin). In later stages of the infection cycle, polyhedrin 
may account for more than 50% of the total protein in an 
infected cell. The polyhedrin gene has been cloned and 
sequenced and its unique features have provided the basis for 
the development of a series ofbaculovirus expression vectors 
(BEYs: Summers, M.D. and Smith, G. E., TAES Bull. 1555 
(1987); Luckow, V. A. and Summers, M.D., Biotechnology 
6:47-55 (1988); Miller, L. K., Ann. Rev. Microbial. 42:177-
179 (1988); U.S. Pat. No. 4,745,051, G. E. Smith and M.D. 
Summers (Filed May 27, 1983; Issued May 17, 1988)). 
45 process is usually required to identify the material or critical 
procedure that has created the viability issue. Problems such 
as poor cell growth and abnormal morphology can result from 
materials that are poor quality, inappropriate, compromised, 
or contaminated and/or equipment that must be re-calibrated 
50 or re-setup to comply with manufacturer usage. Perhaps most 
frustrating, cells of different lots may react differently to 
standardized media and serum supplements resulting in unex-
pected toxicity or nutritional deficiency. Therefore, much of 
the time and expense invested in preparation of protein 
55 expression vectors may be lost when a protein production 
facility experiences difficulty in optimizing cell culture pro-
tein production conditions. As such it would be of great 
economic benefit to provide a generalized agent to a cell line 
to increase its viability, longevity and protein production BEYs are recombinant baculoviruses in which the coding 
sequence for polyhedrin has been replaced with the coding 
sequence for a desired protein. In general, this approach 
involves the construction and isolation of recombinant bacu-
loviruses in which the coding sequence for the chosen gene 
has been inserted behind the promoter for the nonessential 
polyhedrin viral gene (Pennica, eta!, Mol. Cell. Bioi. 4:399- 65 
406 (1984); Smith, eta!, L. Viral. 46:584-593 (1983); Smith, 
60 capacity. 
Insects, like other animals, have effective immune systems 
to combat both biotic and abiotic foreign invasion. Interest-
ingly, endoparasitic insects spend a part of their life cycle 
inside the body of other insect hosts. Considerable effort has 
been expended investigating the mechanism by which these 
endoparasitic insects avoid the host immune system in this 
parasitic relationship. G. E. and M. D. Summers, Mol. Cell. Bioi. 3:2156-2165 
US 7,629,160 B2 
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One well characterized parasitoid-host system in which 
there is immune system evasion is that of the endoparasitic 
wasp Campoletis sonorensis and its host, the tobacco bud-
worm Heliothis virescens. In investigating how immunosup-
pression is regulated in this system, it became apparent that a 
group of wasp viruses, known generically as polydnaviruses 
(PDVs), play a role in the suppression of the host immune 
system. Bracoviruses (BVs) and ichnoviruses (IVs) are the 
two main parasitic wasp associated PDVs. It is known that 
during oviposition, the endoparasitic insect, for example C. 10 
sonorensis, injects not only eggs but also polydnavirus and 
oviduct proteins. Shortly thereafter, the host insect immune 
system begins to show evidence of altered activity and the 
endoparasitoid eggs remain free from encapsulation. The pre-
cise mechanism of this immune suppression is not presently 15 
understood. 
The WHv1.0, WHv1.6 and VHv1.1 genes of C. sonorensis 
polydnavirus (CsPDV) have been cloned and sequenced. 
These genes are described as members of a polydnavirus 
"cysteine-rich" gene family. (Dib-Hajj et a!., Proc. Nat!. 20 
Acad. Sci. (USA) 90: 3765 (1993)). It has been conjectured 
that these genes may play a role in preventing the recognition 
of foreign objects and/or the normal response of components 
4 
acid of SEQ ID NO: 3 under stringent conditions wherein the 
nucleic acid encodes a polypeptide capable of enhancing 
longevity and/or protein production of a cell line in which it is 
expressed. Another aspect of the invention relates to a 
vankyrin expression vector comprising a nucleic acid of SEQ 
ID NO: 1. Yet another aspect relates to a vankyrin expression 
vector comprising a nucleic acid of SEQ ID NO: 3. 
Another aspect of the invention relates to a recombinant 
cell comprising a first nucleic acid selected from the group 
consisting of a nucleic acid encoding the polypeptide of SEQ 
ID NO: 2 a nucleic acid that hybridizes to the nucleic acid of 
SEQ ID NO: 1 under stringent conditions wherein the nucleic 
acid encodes a polypeptide capable of enhancing longevity 
and/or protein production of a cell line in which it is 
expressed; and a nucleic acid of SEQ ID NO: 1; and/or a 
second nucleic acid selected from the group consisting of: a 
nucleic acid encoding the polypeptide of SEQ ID NO: 4; a 
nucleic acid that hybridizes to the nucleic acid of SEQ ID NO: 
3 under stringent conditions wherein the nucleic acid encodes 
a polypeptide capable of enhancing longevity and/or protein 
production of a cell line in which it is expressed; and a nucleic 
acid of SEQ ID NO: 3. 
Another aspect of the invention relates to a method of 
enhancing target protein production of a cell line producing a 
target protein comprising transforming cells of the cell line 
with a vankyrin expression vector, growing the cell line; and 
isolating the target protein from the cell line. 
Another aspect of the invention relates to a method of 
generating a recombinant cell line capable of enhanced target 
of the immune system. (S=ers eta!., Proc. Natl.Acad. Sci. 
(USA) 92: 29 (1995)). Indeed, the VHv 1.1 gene product of 25 
the C. sonorensis polydnavirus has been implicated in the 
inhibition of the cellular immune response. This 30 kDa pro-
tein is shown by indirect immunofluorescence to bind both 
granulocytes and plasmatocytes and is thought to inhibit 
encapsulation. (Li eta!., J. Viral., 68: 7482 (1994)). 
Recent PDV genome sequencing projects have revealed a 
novel family of closely related genes that exist in several 
genomes including, but not limited to, the C. sonorensis IV 
(CsiV) Hyposoter fugitivus IV (HfiV), Glyptafumiferana IV 
(GfiV), Microplitis demolitor BV (MdBV), Cotesia congre- 35 
gata BV (CcBV), Glyptapanteles indiensis BV (GiBV), and 
Toxoneuron nigriceps BV (TnBV) genomes. This family of 
genes has been named vankyrins as their open reading frames 
(ORFs) encode proteins almost exclusively made up of 
ankyrin repeat domains. The PDV ankyrin repeat-carrying 40 
proteins show significant identity to the ankyrin repeats of the 
IK~ family of transcription factor inhibitors suggesting that 
they disrupt intracellular NF -K~ mediated signal transduction 
cascades known to play a role in both vertebrate and inverte-
brate immune responses. There are seven vankyrin ORFs 45 
encoded by the CsiV genome. 
30 protein production comprising transforming a cell line with a 
heterologous nucleic acid encoding and driving the expres-
sion of a target protein; and transforming cells of the cell line 
with a vankyrin expression. 
The inventors have discovered that the expression of two 
CsiV vankyrins from a heterologous expression vector sys-
tem increases the vitality, longevity, and therefore the protein 
productive capacity of cells in culture. 
All references cited herein are hereby incorporated by ref-
erence in their entirety for all purposes. 
SUMMARY OF THE INVENTION 
One aspect of the invention relates to a vankyrin expression 
vector comprising a nucleic acid encoding the polypeptide of 
SEQ ID NO: 2. Another aspect of the invention relates to a 
vankyrin expression vector comprising a nucleic acid encod-
ing the polypeptide of SEQ ID NO: 4. Yet another aspect of 
the invention relates to a vankyrin expression vector compris-
ing a nucleic acid that hybridizes to the nucleic acid of SEQ 
Yet another aspect of the invention relates to a method of 
generating a recombinant target protein-producing cell line 
capable of enhanced target protein production comprising 
constructing a vankyrin expression vector and transforming 
cells of the cell line with the vankyrin expression vector. 
Another aspect of the invention relates to a method of 
enhancing longevity of a cell line producing a target protein 
comprising transforming cells of the cell line with a vankyrin 
expression vector, to obtain a transformed cell line producing 
a target protein; growing the transformed cell line producing 
a target protein longer than a the cell line not transformed with 
the vector. 
Additional advantages of the present invention will 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
embodiment of the invention is shown and described, simply 
50 by way of illustration of the best mode contemplated of car-
rying out the invention. As will be realized, the invention is 
capable of other and different embodiments, and its several 
details are capable of modifications in various obvious 
respects, all without departing from the invention. The 
55 present invention may be practiced without some or all of 
these specific details. In other instances, well known process 
operations have not been described in detail, in order not to 
unnecessarily obscure the present invention. Accordingly, the 
drawings and description are to be regarded as illustrative in 
60 nature, and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
ID NO: 1 under stringent conditions wherein the nucleic acid 
encodes a polypeptide capable of enhancing longevity and/or 
protein production of a cell line in which it is expressed. A 65 
further aspect of the invention relates to a vankyrin expression 
vector comprising a nucleic acid that hybridizes to the nucleic 
FIG. 1. Morphology of 4-day post infected (4 d p.i.) Sf9 
(panel A) and S1-2 (panel B) cells exposed to recombinant 
AcMNPV's expressing CsiV vankyrin proteins. Cells 
infected with recombinant viruses expressing fat body spe-
US 7,629,160 B2 
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cific P-ank:-1 and f -ank:-3 proteins (asterisks) are more stable 
and resemble non-infected cells at 4 d p.i. Cells exposed to 
recombinant viruses expressing the remaining CsiV genes 
undergo apoptosis and lysis by 4 d p.i. and resemble cells 
infected with wild type AcMNPV. 40x magnification. 
FIG. 2. Protein expression is extended in Sf9 cells infected 
with recombinant AcMNPV expressing Fat-Body specific 
CsiV ankyrin genes P-ank:-1 and I2 -ank:-3. Western blots rep-
resent detection of proteins in freshly overlayed culture media 
presented to cells at each subsequent day following infection. 
The CsiV vankyrin genes are intracellular proteins and lack 
secretory signals, thus protein detected in the media overlay is 
the result of that released by cell lysis or rupture following 
infection. Delayed detection of proteins from P-ank:-1 and 
I2 -ank-3 viruses until day 3 p.i. is resultant of the enhanced 
longevity of Sf9 cells occurring early during infection by 
these viruses (as evidenced in FIG. 1). 
FIG. 3. The eDNA and amino acid sequences of P-ank:-1 
(SEQ ID NO: 1 and 3, respectively) and I2 -ank-3 (SEQ ID 
NO: 2 and 4, respectively). 
FIG. 4. Morphology of Sf9 cells exposed to recombinant 
AcMNPV's expressing CsiV vankyrin proteins over time. 
Cells infected with recombinant viruses expressing fat body 
specific P-ank:-1 and I2 -ank-3 proteins (asterisks) are more 
stable and increase the longevity of the cells through 6 days ( 6 
D) post infection such that they resemble non-transfected 
control cells. Cells exposed to recombinant viruses express-
ing the remaining CsiV genes undergo apoptosis and lysis by 
4 d p.i. and resemble cells infected with wild type AcMNPV. 
40x magnification. 
FIG. 5. Morphology ofS1-2 cells exposed to recombinant 
AcMNPV's expressing CsiV vankyrin proteins over time. 
Cells infected with recombinant viruses expressing fat body 
specific P-ank:-1 and I2 -ank-3 proteins (asterisks) are more 
stable and maintain the vitality of the cells through 6 days ( 6 
D) post infection such that they resemble non-transfected 
control cells. Cells exposed to recombinant viruses express-
ing the remaining CsiV genes undergo apoptosis and lysis by 
4 d p.i. and resemble cells infected with wild type AcMNPV. 
40x magnification. 
FIG. 6. Shows the yield of recombinant vankyrin protein 
produced in cells infected by different recombinant AcMN-
PVs. A cell line was infected with different recombinant 
AcMNPVs encoding different vankyrin proteins. Next, the 
vankyrin protein encoded by the each differing recombinant 
AcMNPV was isolated and quantified. The inventors note 
that cells infected by recombinant AcMNPVs encoding 
P-ank:-1 and I2 -ank:-3 produced significantly larger quantities 
of their encoded CsiV vankyrin proteins, i.e., P-ank:-1 and 
I2 -ank:-3 protein, respectively, than cells transgenically 
expressing the other CsiV vankyrin proteins. 
DETAILED DESCRIPTION OF THE INVENTION 
It is an object of the current invention to provide methods 
and compositions relating to the expression ofvankyrin pro-
teins in cell lines to increase their viability, longevity and 
capacity for protein production. The vankyrin gene family 
comprises 7 genes on CsiV genome segments P and I2 . Each 
vankyrin gene encodes an open reading frame of about 500-
bp possessing 4 ankyrin repeat protein motifs. The vankyrin 
protein motifs show significant identities to ankyrin motifs of 
Cactus, the Drosophila IKB protein. MdBV and CsiV 
vankyrin genes align with the 4 C-terminal ankyrin repeat 
domains ofiKBs but lack N-terminal repeats that function to 
mask nuclear localization signals (NLS) and sequester unin-
duced NF -KB dimers in the cytoplasm. 
6 
The seven vankyrin genes are f -ank:-1, I2 -ank:-2, I2 -ank:-3, 
P-ank:-1, P-ank:-2, P-ank:-3 and P-ank:-4. The inventors have 
discovered that the expression of P-ank:-1 and I2 -ank:-3 pro-
teins in cell culture has increased the cells' viability, longevity 
and, therefore, capacity for endogenous and/or heterologous 
target protein production. Specifically, the present invention 
relates to the enhanced expression of endogenous and/or het-
erologous target proteins/polypeptides in recombinant cells 
that are also expressing P-ank -1 and/ orl2 -ank-3 protein com-
10 pared to expression host cells that are not expressing P-ank:-1 
and/or f-ank:-3 protein. 
Before describing the invention in greater detail the fol-
lowing definitions are set forth to illustrate and define the 
meaning and scope of the terms used to describe the invention 
15 herein: 
The term "nucleic acid molecule" is meant to include 
DNA, RNA and mixed DNA-RNA sequences. In addition to 
the typically found A, T, U, G and C residues, a nucleic acid 
molecule may also include related residues such as, for 
20 example, inosine (I). 
The term "polynucleotide" or "oligonucleotide" as used 
herein refers to a polymeric form of nucleotides of any length, 
either ribonucleotides or deoxyribonucleotides. This term 
refers only to the primary structure of the molecule. Thus, this 
25 term includes double and single stranded DNA, triplex DNA, 
as well as double and single stranded RNA. It also includes 
modified, for example, by methylation and/ or by capping, and 
unmodified forms of the polynucleotide. 
The term "promoter region" refers to a DNA sequence that 
30 functions to control the transcription of one or more nucleic 
acid sequences, located upstream with respect to the direction 
of transcription of the transcription initiation site of the gene, 
and is structurally identified by the presence of a binding site 
for DNA-dependent RNA polymerase, transcription initia-
35 tion sites and any other DNA sequences, including, but not 
limited to transcription factor binding sites, repressor and 
activator protein binding sites, calcium or cAMP responsive 
sites, and any other nucleotide sequences known to act 
directly or indirectly to regulate transcription from the pro-
40 mater. 
The term "heterologous DNA" or "heterologous RNA" 
refers to DNA or RNA that does not occur naturally as part of 
the genome or DNA or RNA sequence in which it is present, 
or in which it is found, a cell or location or locations in the 
45 genome or DNA or RNA sequence that differs from that 
which it is in found in nature. Heterologous DNA or RNA is 
not endogenous to the cell into which it is introduced, but has 
been obtained from another cell or synthetically or recombi-
nantly produced. Generally, though not necessarily, such 
50 DNA encodes RNA and protein not normally produced by the 
cell in which the DNA is transcribed or expressed. Similarly 
exogenous RNA encodes protein not normally expressed in 
the cell in which the exogenous RNA is present. Heterologous 
DNA or RNA may also be referred to as foreign DNA or 
55 RNA. Any DNA or RNA that one of skill in the art would 
recognize as heterologous or foreign to the cell in which it is 
expressed is herein encompassed by the term heterologous 
DNA or heterologous RNA. Examples ofheterologous DNA 
include, but are not limited to, DNA that encodes a protein, 
60 polypeptide, reporter nucleic acid sequence, transcriptional 
or translational regulatory sequences, selectable or traceable 
marker protein, such as a protein that confers drug resistance, 
RNA including mRNA and antisense RNA, and ribozymes. 
The term "recombinant polynucleotide" as used herein 
65 refers to a polynucleotide of genomic, eDNA, semisynthetic 
or synthetic origin which, by virtue of its origin or manipu-
lation: (1) is not associated with all or a portion of the poly-
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nucleotide with which it is associated in nature and/or (2) is 
linked to a polynucleotide other than that to which it is linked 
in nature. The term "eDNA" or "complementary DNA" refers 
to single stranded or double stranded DNA sequences 
obtained by reverse transcription of messenger RNA isolated 
from a donor cell. For example, treatment of messenger RNA 
with a reverse transcriptase such as AMV reverse tran-
scriptase or M-MuLV reverse transcriptase in the presence of 
8 
SEQ ID NOs: 1 and 3. Such sequences may differ from SEQ 
ID NOs: 1 and 3, respectively, with regard to the identity of at 
least one nucleotide base. 
However, all polynucleotides sequences "substantially 
identical" to SEQ ID NOs: 1 and 3 hybridize under stringent 
conditions (as defined herein) to all or a portion of the 
complements of SEQ ID NOs: 1 and3 (i.e., target sequences), 
respectively. The terms "hybridize(s) specifically" or "spe-
an oligonucleotide primer will furnish an RNA-DNA duplex 
which can be treated with RNase H, DNA polymerase and 10 
DNA ligase to generate double stranded eDNA. If desired, the 
double stranded eDNA can be denatured by conventional 
techniques such as shearing to generate single stranded 
cifically hybridize(s)" refer to complementary hybridization 
between an oligonucleotide (e.g., a primer or labeled probe) 
and a target sequence. The term specifically embraces minor 
mismatches that can be accommodated by reducing the strin-
gency of the hybridization media to achieve the desired prim-
ing for the PCR polymerases or detection of hybridization eDNA. 
The term "operably linked" refers to the linkage of a DNA 
segment to another DNA segment in such a way as to allow 
the segments to function in their intended manners. A DNA 
sequence encoding a gene product is operably linked to a 
regulatory sequence when it is ligated to the regulatory 
sequence, such as, for example, promoters, enhancers and/or 
silencers, in a manner which allows modulation of transcrip-
tion of the DNA sequence, directly or indirectly. For example, 
a DNA sequence is operably linked to a promoter when it is 
ligated to the promoter downstream with respect to the tran-
scription initiation site of the promoter, in the correct reading 
frame with respect to the transcription initiation site, and 
allows transcription elongation to proceed through the DNA 
sequence. An enhancer or silencer is operably linked to a 
DNA sequence coding for a gene product when it is ligated to 
the DNA sequence in such a manner as to increase or 
decrease, respectively, the transcription of the DNA 
sequence. Enhancers and silencers may be located upstream, 
downstream or embedded within the coding regions of the 
DNA sequence. A DNA for a signal sequence is operably 
linked to DNA coding for a polypeptide if the signal sequence 
is expressed as a preprotein that participates in the secretion 
of the polypeptide. Linkage of DNA sequences to regulatory 
sequences is typically accomplished by ligation at suitable 
restriction sites or via adapters or linkers inserted in the 
sequence using restriction endonucleases known to one of 
skill in the art. 
The term "target" protein or polypeptide, refers to a protein 
of interest that is expressed in the recombinant cells also 
expressing P-ank-1 and/or f-ank-3 protein. Preferably, the 
recombinant cell is used as bioreactor for the production of 
the target protein. The target protein may be an endogenous 
protein naturally produced by the host cell type. For example, 
if the host cell type is a hybridoma, the target protein may be 
a monoclonal antibody. Alternatively, the target protein can 
be encoded by a heterologous recombinant nucleic acid, e.g. 
a eDNA. In this case, the target protein will be a heterologous 
protein, i.e., one that is not naturally expressed by the host cell 
line. 
Central to the invention is the "vankyrin expression vec-
tor." A vankyrin expression vector is any genetic element, 
e.g., a plasmid, chromosome, virus, capable ofbringing about 
the expression of a P-ank-1 (SEQ ID NO: 2) and/or f -ank-3 
(SEQ NO: 4) proteins or proteins substantially similar 
thereto, i.e., those having similar amino acid sequences and 
the same functionalities with regard to the ability to provide 
enhanced cell longevity and/or protein productive capacity. 
Preferably, proteins P-ank-1 (SEQ ID NO: 2) and I2 -ank-3 
(SEQ NO: 4) are encoded by SEQ ID NO: 1 and SEQ NO: 3, 
respectively. The skilled artisan will also appreciate that 
invention also encompasses vankyrin expression vector 
sequences comprising sequences substantially identical to 
15 signal. 
Under stringent hybridization conditions, only highly 
complementary, i.e., substantially identical nucleic acid 
sequences, hybridize. Preferably, such conditions prevent 
hybridization of nucleic acids having 3 or more mismatches 
20 out of 20 contiguous nucleotides, more preferably 2 or more 
mismatches out of 20 contiguous nucleotides, most prefer-
ably one or more mismatch out of 20 contiguous nucleotides. 
The hybridizing portion of the hybridizing nucleic acid is at 
least about 90%, preferably at least about 95%, or most pref-
25 erably about at least about 98%, identical to the sequence of 
a target sequence, or its complement. 
Hybridization of a nucleic acid to a nucleic acid sample 
under stringent conditions is defined below. Nucleic acid 
duplex or hybrid stability is expressed as a melting tempera-
30 ture (T m), which is the temperature at which the probe disso-
ciates from the target DNA. This melting temperature is used 
to define the required stringency conditions. If sequences are 
to be identified that are substantially identical to the probe, 
rather than identical, then it is useful to first establish the 
35 lowest temperature at which only homologous hybridization 
occurs with a particular concentration of salt (e.g. SSC or 
SSPE). Then assuming that 1% mismatching results in a 1 o C. 
decrease in T m' the temperature of the final wash in the 
hybridization reaction is reduced accordingly (for example, if 
40 sequences having >95% identity with the probe are sought, 
the final wash temperature is decrease by 5° C.). In practice, 
the change in T m can be between 0.5° C. and 1.5° C. per 1% 
mismatch. 
Stringent conditions involve hybridizing at 68° C. in 
45 5xSSC/5xDenhardt's solution/1.0% SDS, and washing in 
0.2xSSC/0.1% SDS at room temperature. Moderately strin-
gent conditions include washing in 3xSSC at 42° C. Addi-
tional guidance regarding such conditions is readily available 
in the art, for example, Sambrook, Fischer and Maniatis, 
50 Molecular Cloning, a laboratory manual, (2nd ed.), Cold 
Spring Harbor Laboratory Press, New York, (1989) and F. M. 
Ausubel et a! eds., Current Protocols in Molecular Biology, 
John Wiley and Sons (1994). 
Moreover, vankyrin expression vector containing poly-
55 nucleotides "substantially similar or identical" to SEQ ID 
NO: 1 and 3, respectively, are capable of providing a cell line 
with enhanced longevity and/or protein production capabil-
ity. In one embodiment, when expressed in Sf9 or S1-2 cells, 
polynucleotides "substantially similar or identical" to SEQ 
60 ID NO: 1 and 3, respectively, are capable of improving the 
longevity of those cells to such an extent that they resemble 
non-transfected Sf9 or S1-2 cells, whereas Sf9 or S1-2 cells 
transfected with a vector not containing polynucleotides 
"substantially similar or identical" to SEQ ID NO: 1 and 3, 
65 respectively. Preferably, the vector is a baculovirus vector. In 
another embodiment, polynucleotides "substantially similar 
or identical" to SEQ ID NO: 1 and 3, respectively, are capable 
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of providing enhanced protein production in a cell line in 
which they are expressed, relative to a host cell line trans-
fected in a similar manner by a vector lacking such polynucle-
otides. For example, polynucleotides "substantially similar or 
identical" to SEQ ID NO: 1 and 3, respectively, when 
expressed in Sf9 or S1-2 cells, are capable providing 
enhanced protein production in those cells, relative to Sf9 or 
10 
of those and other strains are fonnd in G. E. Smith and M.D. 
Summers, Viral., 89:517-527 (1978). 
Plasmids for the aforementioned BEYS carrying SEQ ID 
NO: 1 and/or 3, or sequences substantially similar thereto, 
may be designed according to conventional techniques 
known in the art and as described in M.D. Summers and G. E. 
Smith, A Manual of Methods for Baculovirus Vectors and 
Insect Cell Culture Procedures, Texas Agricultural Experi-
ment Station Bulletin No. 1555, Texas A&M University 
S 1-2 cells transfected with a vector not containing polynucle-
otides "substantially similar or identical" to SEQ ID NO: 1 
and 3, respectively. 10 (1987) ("Bulletin No. 1555"). (See also V. A. Luckow and M. 
The vankyrin expression vector contains sequences to 
facilitate expression of P-ank-1 and/or I2 -ank-3 proteins in 
the host cell. Such sequences differ depending on the host 
organism; they include promoter sequences, for example but 
not limited to a polyhedrin promoter, SV40 promoter, or a 15 
conditionally activated promoter such as a metallothionein 
promoter to effect transcription; enhancer sequences to 
increase transcription; ribosomal binding site sequences; and 
transcription and translation termination sequences. The vec-
tor may also optionally behave either as an autonomous unit 20 
of polynucleotide replication within a cell (i.e., capable of 
replication nnder its own control) or being rendered capable 
of replication by insertion into a host cell chromosome, hav-
ing attached to it another polynucleotide segment, so as to 
bring about the replication. Suitable vectors include, but are 25 
not limited to, viruses, plasmids, bacteriophages, yeast arti-
ficial chromosomes (YACs ), cosmids, and the like. Vectors 
may contain polynucleotide sequences which are necessary 
to effect ligation or insertion of the vector into a desired host 
cell and the expression of its coding region(s ). Additionally, 30 
the vankyrin expression vector itself may also contain heter-
ologous nucleic acids encoding and driving the expression of 
target heterologous proteins and/or reporter proteins. 
The skilled artisan will recognize that a wide range of 
vectors may be constructed to permanently, constitutively, 35 
conditionally or transiently drive P-ank-1 and/or f-ank-3 
expression in a wide range of insect and mammalian cell 
lines. The skilled artisan would know how to operably link the 
aforementioned sequences. It is to be understood that this 
invention is intended to include other forms of expression 40 
vectors, host cells and transformation techniques which serve 
equivalent functions and which become known to the art 
hereto. 
D. Summers, Viral., 170:31-39 (1989)). In the preferred 
embodiment, the Baculovirus Expression Vector System 
from BD Biosciences Pharmingen is used which employs a 
modified Autographa californica nuclear polyhedrosis virus 
(AcNPV) genome-BD BaculoGold™ DNA, and an appro-
priate transfer vector. The diversity of AcNPV-based transfer 
vectors, combined with available S. frugiperda Sf9 and Sf21 
cell lines, establish baculovirus expression as a preferred 
system for functional eukaryotic gene expression and the 
large-scale production of recombinant proteins. 
Although the methodology described herein is believed to 
contain sufficient detail to enable one skilled in the art to 
practice the present invention, the plasmids can be con-
structed and purified using standard recombinant DNA tech-
niques described in T. Maniatis, E. F. Fritsch and J. Sam-
brook, Molecular Cloning: A Laboratory Manual, Cold 
Spring Harbor Laboratory (1982) under the current regula-
tions described in United States Dept. of HEW, National 
Institute of Health (NIH) Guidelines for Recombinant DNA 
Research. These references include procedures for the fol-
lowing standard methods: cloning procedures with E. coli 
plasmids, transformation of E. coli cells, plasmid DNA puri-
fication, phenol extraction of DNA, ethanol precipitation of 
DNA, agarose gel electrophoresis, purification of DNA frag-
ments from agarose gels, and restriction endonuclease and 
other DNA-modifYing enzyme reactions. Accordingly, these 
available references are incorporated herein by reference. 
A "reporter nucleic acid sequence" is a DNA molecule that 
expresses a detectable gene product, which may be reporter 
RNA or reporter protein. The detection may be accomplished 
by any method known to one of skill in the art. For example, 
detection of mRNA expression may be accomplished by 
using Northern blot analysis and detection of protein may be 
accomplished by staining with antibodies specific to the pro-The preferred "vankyrin expression vector" is part of a 
baculovirus expression system engineered to express P-ank-1 
and/or I2 -ank-3 proteins nnd the control of a polyhedrin pro-
moter in the cells it infects. Most, preferably, the baculovirus 
45 tein, e.g. Western blot analysis. Preferred reporter nucleic 
acid sequences are those that are readily detectable. A 
reporter nucleic acid sequence may be operably linked in a 
DNA construct with a regulatory DNA sequence such that 
detection of the reporter nucleic acid sequence product pro-
is an Autographa californica baculovirus (AcNPV), and 
expression of P-ank-1 and/or I2 -ank-3 protein is driven by a 
polyhedrin promoter. The baculovirus Autographa califor-
nica mono nuclear polyhedrosis virus (AcMNPV), used in 
the examples as the original source of viral DNA was isolated 
according to procedures described in G. E. Smith and M.D. 
Summers, Virology, 89:517-527 (1978) and G. E. Smith and 
M.D. Summers, J. Viral., 39:125-137 (1981). According to 55 
the preferred embodiment of this invention, a particular strain 
of AcMNPV, E2, is utilized. However, those skilled in the art 
who have the benefit of this disclosure will recognize that 
other baculoviruses and other baculovirus strains may also be 
suitably utilized to obtain viral DNA. In particular, it is 
expected that at least the closely related and naturally occur-
ring strains, Trichoplusia ni MNP\1, Rachiplusia au MNP\1, 
Galleria mellonella MNPV and any plaque-purified strains 
such as the M3' R9, S1 and S3 strains of AcMNPV isolated 
and characterized in G. E. Smith and M. D. Summers, J. 
Viral., 33:311-319 (1980), as well as Bombyx mori NPV 
(BmNPV) may be utilized to advantage. Further description 
50 vides a measure of the transcriptional activity of the regula-
tory sequence. Examples of reporter nucleic acid sequences 
include, but are not limited to, those coding for alkaline 
phosphatase, chloramphenicol acetyl transferase (CAT), 
luciferase, beta-galactosidase and alkaline phosphatase. 
The terms "transformed" or "transfected" are used inter-
changeably and refer to the process by which exogenous 
DNA or RNA is transferred or introduced into an appropriate 
host cell. Additionally, nucleic acids encoding other heterolo-
gous proteins may be introduced into the host cell. Such 
60 transfected cells include stably transfected cells wherein the 
inserted DNA is rendered capable of replication in the host 
cell. Typically, stable transfection requires that the exogenous 
DNA be transferred along with a selectable marker nucleic 
acid sequence, such as for example, a nucleic acid sequence 
65 that confers antibiotic resistance, which enables the selection 
of the stable transfectants. This marker nucleic acid sequence 
may be ligated to the exogenous DNA or be provided inde-
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pendently by simultaneous cotransfection along with the 
exogenous DNA. Transfected cells also include transiently 
expressing cells that are capable of expressing the RNA or 
DNA for limited periods of time. The transfection procedure 
depends on the host cell being transfected. It can include 
packaging the polynucleotide in a virus as well as direct 
uptake of the polynucleotide. Transformation can result in 
incorporation of the inserted DNA into the genome of the host 
cell or the maintenance of the inserted DNA within the host 
cell in plasmid form. Methods oftransformation/transfection 10 
are well known in the art and include, but are not limited to, 
12 
expression element will allow for increased Mab production 
and lessen the need for a technician to concentrate antibody in 
the supernatant. 
In another embodiment of this aspect of the invention, the 
cells transiently transfected with a vankyrin expression vector 
are also transiently or permanently co-transfected with an 
additional expression element having a heterologous nucleic 
acid sequence encoding and driving the expression of a het-
erologous target protein. 
direct injection, such as microinjection, viral infection, par-
ticularly replication-deficient adenovirus infection, elec-
troporation, lipofection, calcium phosphate-mediated direct 
uptake and the like. 
The term "host cell" generally refers to eukaryotic cells 
and includes any transformable cell which is capable of 
expressing a P-ank-1 and/or I2 -ank-3 proteins and can be, or 
has been, used as a recipient for a vankyrin expression vector. 
Once cells have transiently or stably taken up the vankyrin 
expression vector they are "recombinant" cells. DNA is com-
monly transferred or introduced into recipient mammal cells 
Another aspect of the invention relates to cells in which a 
vankyrin expression element is stably integrated into the 
cells' genome, thus rendering a recombinant cell line that 
provides superior protein productive capacity when com-
pared to its wild type cell counterpart. In one embodiment of 
this aspect of the invention, such a cell line is amenable to 
15 further permanent transfection with an additional expression 
vector carrying a nucleic acid sequence encoding a target 
protein of interest. In another embodiment, such a cell line is 
amenable to transient transfection with an additional expres-
sion vector carrying a nucleic acid sequence encoding a target 
20 protein of interest. In another embodiment, the target proteins 
produced by and harvested from the cells having permanently 
integrated vankyrin expression vectors may be proteins 
endogenously produced by the host cells themselves. 
Yet a further aspect of the invention relates to a vankyrin 
25 expression vector that contains additional nucleic acid 
sequences encoding one or more heterologous target proteins 
of interest. Such a vector could be permanently or transiently 
introduced into a host cell line. 
by calcium phosphate-mediated gene transfer, electropora-
tion, lipofection, viral infection and the like. General meth-
ods, vectors and general considerations for gene transfer and 
expression may be found in M. Kriegler, Gene Transfer and 
Expression: A Laboratory Manual, Stockton Press (1990). 
Direct gene transfer to cells in vivo is achieved by the use of 
modified viral vectors, including retroviruses, adenoviruses, 30 
adena-associated viruses and herpes viruses, liposomes, and 
direct injection of DNA into certain cell types. See, e.g., 
Wilson, Nature, 365: 691-692 (1993); Plautz et al,Annals NY 
Acad. Sci., 716: 144-153 (1994); Farhood eta!, Annals NY 
Acad. Sci., 716: 23-34 (1994) and Hyde eta! Nature, 362: 35 
250-255 (1993). 
The recombinant cells having the "vankyrin expression 
vector" expressing P-ank-1 and/or f-ank-3 proteins are 
mammalian, such as, but not limited to Chinese hamster 
ovary (CHO) cells, COS-7 cells, fibroblasts as well as C127, 
3T3, CHO, HeLa and BHK cell lines. Most preferably, the 
cells are insect cells such as, but not limited to S2 cells, 
Schneider cells, S12 cells, 5B1-4, Tn5, and Sf9 cells. The 
Spodoptera frugiperda Sf9 cell line may be obtained from 
American Type Culture Collection (Rockville, Md.) and is 
assigned accession number ATCC CRL 1711. See M. D. 
Summers and G. E. Smith, Bulletin No. 1555, suora. Those 
skilled in the art who have the benefit of this disclosure will 
40 recognize that other clonal derivatives of the Sf9 cell line as 
well as Trichoplusia ni and other insects such as the silkworm, 
Bombyx mori, or insect cell cultures derived there from can be 
used to advantage. 
Recombinant cells provided by this invention expressing 
P-ank-1 and/or I2 -ank-3 proteins are intended to produce 
target polypeptides, preferably human proteins and frag-
ments thereof. The process involves culturing the recombi-
nant cells under conditions wherein the endogenous or heter-
ologous target proteins are expressed, e.g., by inducing the 
activity of a conditional promoter, and purifYing the target 
protein from the cell culture. Purification of target proteins is 
within the skill set or the skilled artisan and generally involves 
the steps of cell lysis, homogenization, centrifugation and 
separation of the desired protein by processes such as salt 
fractionation, precipitation, and a variety of chromatographic 
methods such as anion exchange chromatography, hydropho-
bic interaction chromatography, high resolution chromatog- 50 
raphy, gel filtration chromatography and the like. 
One aspect of this invention, relates to cells transiently 
expressing a vankyrin expression vector. In one embodiment 
of this aspect of the invention, the transient expression of the 
P-ank-1 and/or I2 -ank-3 proteins serves to temporarily 
strengthen the vitality of the culture expressing them. It is 
envisaged that this temporary increase in vitality will allow 
for the increased production of target proteins produced by 
and harvested from the host cell line. For example, an estab-
lished monoclonal antibody (Mab )-producing hybridoma 
cell line may be transiently transfected with the vankyrin 
expression element to obtain an increase in antibody produc-
tion. The most simple method for in vitro production ofMabs 
The standard methods of insect cell culture, cotransfection 
45 and preparation of plasmids in accordance with the examples, 
are set forth in M.D. S=ers and G. E. Smith, A Manual of 
Methods for Baculovirus Vectors and Insect Cell Culture 
Procedures, Texas Agricultural Experiment Station Bulletin 
No. 1555, TexasA&M University (1987). This reference also 
pertains to the standard methods of cloning genes into AcM-
NPV transfer vectors, plasmid DNA isolation, transferring 
genes into the AcMNPV genome, viral DNA purification, 
radio labelling recombinant proteins and preparation of insect 
cell culture media. Accordingly, this available reference is 
incorporated herein by reference. 
55 The procedures for the cultivation of viruses and cells are 
described in L. E. Volkman and M.D. Summers, J. Viral, 
19:820-832 (1975) andL. E. Volkman, M.D. Summers and C. 
H. Hsieh, J. Viral, 19:820-832 (1976). Viral growth kinetics 
were determined as described by L. E. Volkman, eta!., suora, 
60 using S. frugiperda and a 1.5% agarose overlay. 
Example 1 
is standard tissue culture in either large flasks or roller bottles. 
The production of Mab by hybridomas in tissue culture is 
hybridoma-dependent and can vary between 1-100 flg/ml. 65 
Therefore, it is often necessity to concentrate Mab from 
supernatant. Transfecting a hybridoma with the vankyrin 
For example, when expressed in Sf9 or S1-2 cells, poly-
nucleotides "substantially similar or identical" to SEQ ID 
NO: 1 and 3, respectively, are capable improving the longev-
ity of those cells to such an extent that they resemble non-
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transfected Sf9 or S 1-2 cells, whereas Sf9 or S 1-2 cells trans-
fected with a vector not containing polynucleotides 
"substantially similar or identical" to SEQ ID NO: 1 and 3, 
respectively, rapidly lyse about 4 days post infection. FIG. 1. 
Moreover, the longevity of a cell line expressing polynucle-
otides "substantially similar or identical" to SEQ ID NO: 1 
and 3, respectively, continues to be maintained such that it 
resembles non-infected cells at about 6 to about 7 days post 
infection. FIGS. 2, 4 and 5. Therefore, when an Sf9 or S1-2 
cell line is infected with a AcMNPV comprising polynucle-
otides "substantially similar or identical" to SEQ ID NO: 1 or 
3, respectively, the infected Sf9 or S 1-2 cell line has enhanced 
longevity relative to an Sf9 or S1-2 cell line infected with a 
wild type AcMNPV. 
Example 2 
Polynucleotides "substantially similar or identical" to SEQ 
ID NO: 1 and 3, respectively, are capable of providing 
enhanced protein production in a cell line in which they are 
expressed, relative to a host cell line transfected in a similar 
manner by a vector lacking such polynucleotides. Specifi-
cally, polynucleotides "substantially similar or identical" to 
SEQ ID NO: 1 and 3, respectively, when expressed in Sf9 or 
S1-2 cells, are capable providing enhanced protein produc-
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 4 
<210> SEQ ID NO 1 
<211> LENGTH, 513 
<212> TYPE, DNA 
<213> ORGANISM, Campoletis sonorensis 
<400> SEQUENCE, 1 
14 
tion in those cells, relative to Sf9 or S1-2 cells transfected 
with a vector not containing polynucleotides "substantially 
similar or identical" to SEQ ID NO: 1 and 3, respectively. As 
can be seen in FIG. 2, protein expression is extended in Sf9 
cells infected with recombinant AcMNPV expressing CsiV 
ankyrin genes P-ank-1 and I2 -ank-3. Western blots in FIG. 2, 
represent detection of proteins in freshly overlayed culture 
media presented to cells at each subsequent day following 
infection. The CsiV vankyrin genes are intracellular proteins 
10 
and lack secretory signals, thus protein detected in the media 
overlay is the result of that released by cell lysis or rupture 
following infection. Delayed detection of proteins from 
P-ank-1 and I2 -ank-3 viruses until day 3 post infection is 
resultant of the enhanced longevity of Sf9 cells occurring 
early during infection by these viruses (as evidenced in FIG. 
15 1). Additionally, because cells expressing polynucleotides 
"substantially similar or identical" to SEQ ID NO: 1 and 3, 
respectively, are able to produce proteins for a longer period 
of time, they are able to produce more protein in total, thus 
providing an enhanced protein production capability. There-
20 fore, when an Sf9 or S 1-2 cell line is infected with aAcMNPV 
comprising polynucleotides "substantially similar or identi-
cal" to SEQ ID NO: 1 or 3, respectively, the infected Sf9 or 
S 1-2 cell line has enhanced protein production relative to an 
Sf9 or S 1-2 cell line infected with a wild type AcMNPV. 
atggagattt ctcaaattcg aaagctattc ggtaaaaacc gcgtcacgaa aaataccata 60 
tttcacgagc ttgcccacgc 
gacgagccat gcagctctat 
gtggcggcaa agacgcaccg 
ttaggggcaa acctgaatgc 
gttgagcgag acgattacgt 
gatgcaagag gttgggatgg 
gagatgatgg atattttccg 
gtgaatgaaa gtacatcgaa 
<210> SEQ ID NO 2 
<211> LENGTH, 171 
<212 > TYPE, PRT 
tggatcattg acactactgt 
cctgcaagag gttaatgctg 
aggacagctt gcagtgagga 
gaaagatcgt gtctggaact 
cctcgcaaag tggctgcgcc 
acttacggca catgaaacgt 
aaccgacggt gttaacagag 
tgacaatcag cat 
<213> ORGANISM: Campoletis sonorensis 
<400> SEQUENCE, 2 
accgggttcg agacaacatt 
atggagacta tagtatccat 
tcatacaggt gctactagag 
ttactgtact gcatgtcgca 
atcacccaca aattgatttg 
cgttgataac gtgcaacaaa 
ccggtggtac agagccgaaa 
Met Glu Ile Ser Gln Ile Arg Lys Leu Phe Gly Lys Asn Arg Val Thr 
1 5 10 15 
Lys Asn Thr Ile Phe His Glu Leu Ala His Ala Gly Ser Leu Thr Leu 
20 25 30 
Leu Tyr Arg Val Arg Asp Asn Ile Asp Glu Pro Cys Ser Ser Ile Leu 
35 40 45 
120 
180 
240 
300 
360 
420 
480 
513 
US 7,629,160 B2 
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-continued 
Gln Glu Val Asn Ala Asp Gly Asp Tyr Ser Ile His Val Ala Ala Lys 
50 55 60 
Thr His Arg Gly Gln Leu Ala Val Arg Ile Ile Gln Val Leu Leu Glu 
65 70 75 80 
Leu Gly Ala Asn Leu Asn Ala Lys Asp Arg Val Trp Asn Phe Thr Val 
85 90 95 
Leu His Val Ala Val Glu Arg Asp Asp Tyr Val Leu Ala Lys Trp Leu 
100 105 110 
Arg His His Pro Gln Ile Asp Leu Asp Ala Arg Gly Trp Asp Gly Leu 
115 120 125 
Thr Ala His Glu Thr Ser Leu Ile Thr Cys Asn Lys Glu Met Met Asp 
130 135 140 
Ile Phe Arg Thr Asp Gly Val Asn Arg Ala Gly Gly Thr Glu Pro Lys 
145 150 155 160 
Val Asn Glu Ser Thr Ser Asn Asp Asn Gln His 
165 170 
<210> SEQ ID NO 3 
<211> LENGTH, 513 
<212> TYPE, DNA 
<213> ORGANISM, Campo let is sonorensis 
<400> SEQUENCE, 3 
atggaaaatt ctcaaattgc 
tttcacgagc ttgcccacgc 
caagagccat gcagctctat 
gtggcggcaa aaacgcaccg 
ttgggggcta atctgaatgc 
gttgagcggg aggattacgt 
aatgcgagag gtttcgctgg 
aagatgatgg atattttccg 
gtgaatgaaa gtacatcgaa 
<210> SEQ ID NO 4 
<211> LENGTH, 171 
<212> TYPE, PRT 
aaagctgttc ggtacaaact 
tggatcgttg acacttcttc 
cctgcaagag gttaatgcta 
aggacagctc gcagtgagga 
aagagatcgt gtctggaact 
cctcacaatg tggctgcgcc 
acttacggca catcaaatgg 
aaccgacgct gtatacggag 
tgacaatcag cat 
<213> ORGANISM: Campoletis sonorensis 
<400> SEQUENCE, 4 
gggtcacgaa aaataccata 
accgggttcg acacaacatt 
atggagacta tagtattcat 
tcattcagat actactggaa 
ttactgtact gcatgtcgca 
atcacccaca aatggatttg 
cgttgatgtc gtgcgacaga 
ccggtggttc agagccgaaa 
Met Glu Asn Ser Gln Ile Ala Lys Leu Phe Gly Thr Asn Trp Val Thr 
1 5 10 15 
Lys Asn Thr Ile Phe His Glu Leu Ala His Ala Gly Ser Leu Thr Leu 
20 25 30 
Leu His Arg Val Arg His Asn Ile Gln Glu Pro Cys Ser Ser Ile Leu 
35 40 45 
Gln Glu Val Asn Ala Asn Gly Asp Tyr Ser Ile His Val Ala Ala Lys 
50 55 60 
Thr His Arg Gly Gln Leu Ala Val Arg Ile Ile Gln Ile Leu Leu Glu 
65 70 75 80 
Leu Gly Ala Asn Leu Asn Ala Arg Asp Arg Val Trp Asn Phe Thr Val 
85 90 95 
Leu His Val Ala Val Glu Arg Glu Asp Tyr Val Leu Thr Met Trp Leu 
100 105 110 
16 
60 
120 
180 
240 
300 
360 
420 
480 
513 
US 7,629,160 B2 
17 18 
-continued 
Arg His His Pro Gln Met Asp Leu Asn Ala Arg Gly Phe Ala Gly Leu 
115 120 125 
Thr Ala His Gln Met Ala Leu Met Ser Cys Asp Arg Lys Met Met Asp 
130 135 140 
Ile Phe Arg Thr Asp Ala Val Tyr Gly Ala Gly Gly Ser Glu Pro Lys 
145 150 155 
Val Asn Glu Ser Thr Ser Asn Asp Asn Gln His 
165 170 
What is claimed is: 
1. A vankyrin expression vector comprising the nucleic 
acid sequence encoding the polypeptide of SEQ ID NO: 2 and 
a nucleic acid encoding the polypeptide of SEQ ID NO: 4. 
2. A vankyrin expression vector comprising the nucleic 
acid sequence encoding the polypeptide of SEQ ID NO: 4. 
15 
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3. A vankyrin expression vector comprising a first nucleic 
acid that hybridizes to the full-length complement of the 
nucleic acid of SEQ ID NO: 1 under stringent conditions 
comprising hybridizing at 68° C. in 5xSSC/5xDenhardt's 
solution/1.0% SDS, and washing in 0.2xSSC/0.1% SDS at 25 
room temperature; and a second nucleic acid that hybridizes 
to the full-length complement of SEQ ID NO: 3 under strin-
gent conditions comprising hybridizing at 680 in 5xSSC/5x 
Denhardt's solution/1.0% SDS, and washing in 0.2xSSC/ 
0.1% SDS at room temperature; wherein the first and second 30 
nucleic acids each encode a polypeptide capable of enhancing 
longevity of a cell line in which it is expressed and/or enhanc-
ing production of one or more target proteins optionally 
encoded by the vector compared to wild type cell counterpart 
of the cell line. 
4. A vankyrin expression vector comprising a nucleic acid 
that hybridizes to the full-length complement of SEQ ID NO: 
35 
160 
ii. a first nucleic acid sequence that hybridizes to the 
nucleic acid of SEQ ID NO: 1 under stringent condi-
tions comprising hybridizing at 68° in 5xSSC/5xDen-
hardt's solution/1.0% SDS, and washing in 0.2xSSC/ 
0.1% SDS at room temperature and a second nucleic 
acid sequence that hybridizes to SEQ ID NO: 3 under 
stringent conditions comprising hybridizing at 68° in 
5xSSC/5xDenhardt's solution/1.0% SDS, and wash-
ing in 0.2xSSC/0.1% SDS at room temperature; 
wherein the first and second nucleic acid sequences 
each encode a polypeptide capable of enhancing lon-
gevity and/or protein production of a cell line in which 
it is expressed, compared to wild type cell counterpart 
of the cell line; 
iii. a nucleic acid comprising SEQ ID NO: 1 and SEQ ID 
N0:3; 
iv. a nucleic acid encoding the polypeptide of SEQ ID 
N0:4; 
v. a nucleic acid that hybridizes to the nucleic acid of 
SEQ ID NO: 3 under stringent conditions comprising 
hybridizing at 680 in 5xSSC/5xDenhardt's solution/ 
1.0% SDS, and washing in 0.2xSSC/0.1% SDS at 
room temperature; wherein the nucleic acid encodes a 
polypeptide capable of enhancing longevity and/or 
protein production of a cell line in which it is 
expressed, compared wild type cell counterpart of the 
cell line; and 
vi. the nucleic acid of SEQ ID NO: 3; 
b. growing said cell line; and 
c. isolating said target protein from said cell line. 
3 under stringent conditions comprising hybridizing at 680 in 
5xSSC/5xDenhardt's solution/1.0% SDS, and washing in 
0.2xSSC/0.1% SDS at room temperature; wherein the 40 
nucleic acid encodes a polypeptide capable of enhancing 
longevity of a cell line in which it is expressed and/or enhanc-
ing production of one or more target proteins optionally 
encoded by the vector compared to wild type cell counterpart 11. A method of generating a recombinant cell line capable 
45 of enhanced target protein production comprising: of the cell line. 
5. A vankyrin expression vector comprising the nucleic 
acid sequence of SEQ ID NO: 1 and the nucleic acid sequence 
ofSEQIDN0:3. 
6. A vankyrin expression vector comprising the nucleic 
acid sequence of SEQ ID NO: 3. 
7. The vankyrin expression vector of any one of claims 1 to 
6 wherein the vankyrin expression vector is a baculovirus 
vankyrin expression vector. 
50 
8. The vector of any one of claims 1 to 6, wherein said 
vector further comprises a nucleic acid encoding a target 55 
protein. 
9. A recombinant cell line comprising any one of the vec-
tors of claims 1 to 6. 
10. A method of enhancing target protein production of a 
cell line producing a target protein comprising: 
a. transforming cells of said cell line with a vankyrin 
expression vector comprising a first polynucleotide 
encoding one or more target proteins; said vankyrin 
expression vector further comprising a second poly-
nucleotide selected from the group consisting of: 
i. a nucleic acid encoding the polypeptide of SEQ ID 
NO: 2 and the polypeptide of SEQ ID NO: 4; 
60 
65 
a. transforming a cell line with a heterologous nucleic acid 
encoding and expressing one or more target proteins; 
and 
b. transforming cells of said cell line with a vankyrin 
expression vector; said vankyrin expression vector com-
prising a polynucleotide selected from the group con-
sisting of: 
i. a nucleic acid encoding the polypeptide of SEQ ID 
NO: 2 and the polypeptide of SEQ ID NO: 4; 
ii. a first nucleic acid sequence that hybridizes to the 
nucleic acid of SEQ ID NO: 1 under stringent condi-
tions comprising hybridizing at 68° in 5xSSC/5xDen-
hardt's solution/1.0% SDS, and washing in 0.2xSSC/ 
0.1% SDS at room temperature and a second nucleic 
acid sequence that hybridizes to SEQ ID NO: 3 under 
stringent conditions comprising hybridizing at 680 in 
5xSSC/5xDenhardt's solution/1.0% SDS, and wash-
ing in 0.2xSSC/0.1% SDS at room temperature; 
wherein the first and second nucleic acid sequences 
each encode a polypeptide capable of enhancing lon-
gevity and/or protein production of a cell line in which 
it is expressed, compared to wild type cell counterpart 
of the cell line; 
US 7,629,160 B2 
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iii. a nucleic acid comprising SEQ ID NO: 1 and SEQ ID 
N0:3; 
iv. a nucleic acid encoding the polypeptide of SEQ ID 
N0:4; 
v. a nucleic acid that hybridizes to the nucleic acid of 5 
SEQ ID NO: 3 under stringent conditions comprising 
hybridizing at 680 in 5xSSC/5xDenhardt's solution/ 
1.0% SDS, and washing in 0.2xSSC/0.1% SDS at 
room temperature; wherein the nucleic acid encodes a 
polypeptide capable of enhancing longevity and/or 
10 
protein production of a cell line in which it is 
expressed, compared to wild type cell counterpart of 
the cell line; and 
vi. the nucleic acid of SEQ ID NO: 3. 
12. A method of generating a recombinant target protein-
producing cell line capable of enhanced target protein pro- 15 
duction comprising: 
a. constructing a vankyrin expression vector; said vankyrin 
expression vector comprising a polynucleotide selected 
from the group consisting of: 
i. a nucleic acid encoding the polypeptide of SEQ ID 20 
NO: 2 and the polypeptide of SEQ ID NO: 4; 
ii. a first nucleic acid sequence that hybridizes to the 
nucleic acid of SEQ ID NO: 1 under stringent condi-
tions comprising hybridizing at 680 in 5xSSC/5x 
Denhardt's solution/1.0% SDS, and washing in 0.2x 25 
SSC/0.1% SDS at room temperature and a second 
nucleic acid sequence that hybridizes to the nucleic 
acid of SEQ ID NO: 3 under stringent conditions 
comprising hybridizing at 68° in 5xSSC/5xDen-
hardt's solution/1.0% SDS, and washing in 0.2xSSC/ 30 
0.1% SDS at room temperature; wherein the first and 
second nucleic acid sequences each encode a 
polypeptide capable of enhancing longevity and/or 
protein production of a cell line in which it is 
expressed, compared to wild type cell counterpart of 
the cell line; 35 
iii. a nucleic acid comprising SEQ ID NO: 1 and SEQ ID 
N0:3; 
iv. a nucleic acid encoding the polypeptide of SEQ ID 
N0:4; 
v. a nucleic acid that hybridizes to the nucleic acid of 40 
SEQ ID NO: 3 under stringent conditions comprising 
hybridizing at 68° in 5xSSC/5xDenhardt's solution/ 
1.0% SDS, and washing in 0.2xSSC/0.1% SDS at 
room temperature; wherein the nucleic acid encodes a 
polypeptide capable of enhancing longevity and/or 45 
protein production of a cell line in which it is 
expressed, compared to wild type cell counterpart of 
the cell line; and 
vi. the nucleic acid of SEQ ID NO: 3; and 
b. transforming cells of said cell line with the vankyrin 50 
expression vector. 
13. A method of enhancing longevity of a cell line produc-
ing a target protein comprising: 
a. transforming cells of said cell line with a vankyrin 
expression vector, said vankyrin expression vector com- 55 
prising a polynucleotide selected from the group con-
sisting of: 
i. a nucleic acid encoding the polypeptide of SEQ ID 
NO: 2 and the polypeptide of SEQ ID NO: 4; 
ii. a first nucleic acid sequence that hybridizes to the 
60 
nucleic acid of SEQ ID NO: 1 under stringent condi-
tions comprising hybridizing at 680 in 5xSSC/5x 
Denhardt's solution/1.0% SDS, and washing in 0.2x 
SSC/0.1% SDS at room temperature and a second 
nucleic acid sequence that that hybridizes to the 
nucleic acid of SEQ ID NO: 3 under stringent condi-
20 
tions comprising hybridizing at 680 in 5xSSC/5x 
Denhardt's solution/1.0% SDS, and washing in 0.2x 
SSC/0.1% SDS at room temperature; wherein the first 
and second nucleic acid sequences each encode a 
polypeptide capable of enhancing longevity and/or 
protein production of a cell line in which it is 
expressed, compared to wild type cell counterpart of 
the cell line; 
iii. a nucleic acid sequence comprising SEQ ID NO: 1 
and SEQ ID NO: 3; 
iv. a nucleic acid encoding the polypeptide of SEQ ID 
N0·4· 
v. a n~cl~ic acid that hybridizes to the nucleic acid of 
SEQ ID NO: 3 under stringent conditions comprising 
hybridizing at 68° in 5xSSC/5xDenhardt's solution/ 
1.0% SDS, and washing in 0.2xSSC/0.1% SDS at 
room temperature; wherein the nucleic acid encodes a 
polypeptide capable of enhancing longevity and/or 
protein production of a cell line in which it is 
expressed, compared to wild type cell counterpart of 
the cell line; and 
vi. the nucleic acid of SEQ ID NO: 3; and 
b. obtaining a transformed cell line having a longevity 
greater than the same cell line lacking said vankyrin 
expression vector. 
14. The method of any one of claims 10-13 wherein said 
cell line is an Spodoptora frugiperda 9 (Sf9) or an Spodoptera 
littoralis 2 cell line. 
15. The method of any one of claims 10-13 wherein said 
vector is a baculovirus expression vector. 
16. The method of any one of claims 10-13 wherein the 
vector is stably transfected or transformed. 
17. The method of any one of claims 10-13, wherein the 
target protein is encoded by a polynucleotide that is heterolo-
gous to the cell line. 
18. The method of any one of claims 10, 12 or 13 wherein 
said target protein is an endogenous protein to the cell line. 
19. The method of any one of claims 10-13 wherein the 
vector is transiently transfected. 
20. An isolated nucleic acid encoding the polypeptide is of 
SEQ ID NO: 2 and the polypeptide of SEQ ID N0:4. 
21. An isolated nucleic acid encoding a polypeptide having 
the sequence of SEQ ID NO: 4. 
22. An isolated nucleic acid comprising a first nucleotide 
sequence that hybridizes to the full length complement of 
SEQ ID NO: 1 under stringent conditions comprising hybrid-
izing at 68° in 5xSSC/5xDenhardt's solution/1.0% SDS, and 
washing in 0.2xSSC/0.1% SDS at room temperature and a 
second nucleic acid sequence that hybridizes to the full length 
complement of SEQ ID NO: 3 under stringent conditions 
comprising hybridizing at 680 in 5xSSC/5xDenhardt's solu-
tion/1.0% SDS, and washing in 0.2xSSC/0.1% SDS at room 
temperature; wherein the first and second nucleic acid 
sequences each encodes a single polypeptide capable of 
enhancing longevity of a cell line in which it is expressed, 
compared to wild type cell counterpart of the cell line. 
23. An isolated nucleic acid that hybridizes to the full 
length complement of SEQ ID NO: 3 under stringent condi-
tions comprising hybridizing at 68° in 5xSSC/5xDenhardt's 
solution/1.0% SDS, and washing in 0.2xSSC/0.1% SDS at 
room temperature; wherein the nucleic acid encodes a 
polypeptide capable of enhancing longevity of a cell line in 
which it is expressed, compared to wild type cell counterpart 
of the cell line. 
24. An isolated nucleic acid consisting of SEQ ID NO: 3. 
* * * * * 
